Case Reports in Pulmonology / 2020 / Article / Tab 1

Case Report

Azathioprine Hypersensitivity Syndrome during Treatment of Severe Interstitial Lung Disease with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

Table 1

Laboratory findings during the course of the disease.

At diagnosis2 years after MMF therapyUnits

WBC12,57010,99010,84010,10019,65016,4106,030/μL
Hb12.212.112.112.31411.810.4mg/dL
Plt43.735.832.819.452.626.734.0104/μL
Alb2.53.13.13.02.43.8mg/dL
LDH209264232300244334206IU/L
AST29183624355022IU/L
ALT37153026283910IU/L
CPK54191738203843IU/L
BUN20.926.128.520.834.170.418.2mg/dL
Cr0.931.401.551.301.666.341.24mg/dL
Na137140138139137136141mEq/L
K4.64.65.54.24.34.94.0mEq/L
Cl104104102103101103100mEq/L
CRP19.922.229.2310.8716.1931.190.43mg/dL
Urine protein2+2+±2+
Urine occult blood3+3+3+3+3+3+2+
Urine sediment (RBC)50-9950-9950-99>100>100>10050-99/HPF
β-D-Glucan9.611.97.7pg/mL
CMV-antigenemianeg.neg.neg.
SP-D<17.223.7mg/dL
KL-61,220469U/mL
IgG731583mg/dL
Anti-MPO-ANCA>300>300>300>300>300U/mL
Anti-GBM-Ab<2.0<2.0U/mL
Anti-PR3-ANCA<1.0U/mL
Anti-nuclear antibody×40

ANCA: anti-neutrophil cytoplasmic antibodies; CMV: cytomegalovirus; GBM: glomerular basement membrane; KL-6: Krebs von den Lungen-6; MMF: mycophenolate mofetil; MPO: myeloperoxidase; PR3: proteinase 3; SP-D: surfactant protein d; RBC: red blood cell.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.